Table of Contents
ISRN Surgery
Volume 2013 (2013), Article ID 685327, 4 pages
http://dx.doi.org/10.1155/2013/685327
Research Article

Gross Hematuria in Patients with Prostate Cancer: Etiology and Management

1Department of Urology, Hadassah Hebrew University Hospital, P.O. Box 12000, Jerusalem 91120, Israel
2Department of Pathology, Hadassah Hebrew University Hospital, P.O. Box 12000, Jerusalem 91120, Israel
3Department of Urology, University of Montreal Hospital Center (CHUM), 1560 Sherbrooke E, Montreal, Quebec, Canada

Received 13 February 2013; Accepted 3 March 2013

Academic Editors: A. H. Al-Salem, A. Parry, and A. Petroianu

Copyright © 2013 Ofer N. Gofrit et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. A. Del Regato, A. H. Trailins, and D. D. Pittman, “Twenty years follow-up of patients with inoperable cancer of the prostate (Stage C) treated by radiotherapy: report of a national cooperative study,” International Journal of Radiation Oncology Biology Physics, vol. 26, no. 2, pp. 197–201, 1993. View at Google Scholar · View at Scopus
  2. A. Harsolia, C. Vargas, D. Yan et al., “Predictors for chronic urinary toxicity after the treatment of prostate cancer with adaptive three-dimensional conformal radiotherapy: dose-volume analysis of a phase II Dose-Escalation Study,” International Journal of Radiation Oncology Biology Physics, vol. 69, no. 4, pp. 1100–1109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Devisetty, K. C. Zorn, M. H. Katz, A. B. Jani, and S. L. Liauw, “External beam radiation therapy after transurethral resection of the prostate: a report on acute and late genitourinary toxicity,” International Journal of Radiation Oncology Biology Physics, vol. 77, no. 4, pp. 1060–1065, 2010. View at Publisher · View at Google Scholar · View at Scopus
  4. J. F. Anderson, D. A. Swanson, L. B. Levy et al., “Urinary side effects and complications after permanent prostate brachytherapy: the MD anderson cancer center experience,” Urology, vol. 74, no. 3, pp. 601–605, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Zapatero, F. García-Vicente, D. Sevillano et al., “Is hormone therapy a protective factor for late hematuria after high-dose radiotherapy in prostate cancer?” Urology, vol. 72, no. 5, pp. 1130–1134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. S. J. Foley, L. Z. Soloman, A. W. Wedderburn et al., “A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride,” Journal of Urology, vol. 163, no. 2, pp. 496–498, 2000. View at Google Scholar · View at Scopus
  7. B. J. R. Barrass, R. Thurairaja, J. McFarlane, and R. A. Persad, “Haematuria in prostate cancer: new solutions for an old problem,” BJU International, vol. 97, no. 5, pp. 900–902, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Leibovici, L. Pagliaro, C. J. Rosser, and L. L. Pisters, “Salvage surgery for bulky local recurrence of prostate cancer following radical prostatectomy,” Journal of Urology, vol. 173, no. 3, pp. 781–783, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Cox, J. Stetz, and T. F. Pajak, “Toxicity criteria of the radiation therapy oncology group (RTOG) and the european organization for cancer research and treatment of cancer (EORTC),” International Journal of Radiation Oncology Biology Physics, vol. 31, no. 5, pp. 1341–1346, 1995. View at Google Scholar
  10. O. S. Din, N. Thanvi, C. J. Ferguson, and P. Kirkbride, “Palliative prostate radiotherapy for symptomatic advanced prostate cancer,” Radiotherapy and Oncology, vol. 93, no. 2, pp. 192–196, 2009. View at Publisher · View at Google Scholar · View at Scopus